AstraZeneca struck a licensing deal for Dizal Pharmaceutical’s EGFR exon 20 insertion lung cancer pill Zegfrovy (sunvozertinib), expanding the pharma’s oral targeted-therapy footprint. The agreement includes a $600 million upfront payment and up to $900 million more tied to development, regulatory, and commercial milestones, with global development and commercialization rights moving to AstraZeneca. The move follows Dizal’s phase 3 WU-KONG28 results, where sunvozertinib outperformed platinum-doublet chemotherapy on progression-free survival in first-line advanced EGFR exon 20 insertion non-small cell lung cancer. Both FDA and China’s CDE have granted Breakthrough Therapy designations for the first-line setting. The licensing underscores how Chinese-origin oncology assets continue to translate into Western pharma balance sheets through deal structures that preserve commercial leverage while accelerating global label expansion.